JP2025507939A5 - - Google Patents
Info
- Publication number
- JP2025507939A5 JP2025507939A5 JP2024552335A JP2024552335A JP2025507939A5 JP 2025507939 A5 JP2025507939 A5 JP 2025507939A5 JP 2024552335 A JP2024552335 A JP 2024552335A JP 2024552335 A JP2024552335 A JP 2024552335A JP 2025507939 A5 JP2025507939 A5 JP 2025507939A5
- Authority
- JP
- Japan
- Prior art keywords
- hla
- allele
- human cancer
- modified human
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263316251P | 2022-03-03 | 2022-03-03 | |
| US63/316,251 | 2022-03-03 | ||
| US202263415475P | 2022-10-12 | 2022-10-12 | |
| US63/415,475 | 2022-10-12 | ||
| PCT/US2023/014337 WO2023167973A1 (en) | 2022-03-03 | 2023-03-02 | Cancer vaccines and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507939A JP2025507939A (ja) | 2025-03-21 |
| JP2025507939A5 true JP2025507939A5 (https=) | 2026-02-26 |
Family
ID=85772911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024552335A Pending JP2025507939A (ja) | 2022-03-03 | 2023-03-02 | がんワクチンおよびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250186568A1 (https=) |
| EP (1) | EP4486371A1 (https=) |
| JP (1) | JP2025507939A (https=) |
| CN (1) | CN119053337A (https=) |
| AU (1) | AU2023227477A1 (https=) |
| CA (1) | CA3254024A1 (https=) |
| IL (1) | IL315361A (https=) |
| WO (1) | WO2023167973A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240156869A1 (en) * | 2021-03-12 | 2024-05-16 | T-Cure Bioscience, Inc. | Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy |
| WO2025171109A1 (en) | 2024-02-07 | 2025-08-14 | Briacell Therapeutics Corp. | Cancer vaccines expressing post-translational modified antigens and methods of use thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5858776A (en) * | 1993-11-03 | 1999-01-12 | Repligen Corporation | Tumor cells with increased immunogenicity and uses therefor |
| DE19832840C1 (de) * | 1998-07-21 | 2000-06-08 | Kerkmann Tucek Aida | Mittel zur Immuntherapie von Tumorerkrankungen |
| US7807186B2 (en) * | 2007-01-17 | 2010-10-05 | University Of Maryland, Baltimore County | Tumor cells from immune privileged sites as base cells for cell-based cancer vaccines |
| WO2017147600A1 (en) | 2016-02-25 | 2017-08-31 | Briacell Therapeutics Corp. | Whole-cell cancer vaccines and methods for selection thereof |
-
2023
- 2023-03-02 WO PCT/US2023/014337 patent/WO2023167973A1/en not_active Ceased
- 2023-03-02 AU AU2023227477A patent/AU2023227477A1/en active Pending
- 2023-03-02 US US18/840,333 patent/US20250186568A1/en active Pending
- 2023-03-02 JP JP2024552335A patent/JP2025507939A/ja active Pending
- 2023-03-02 EP EP23713509.0A patent/EP4486371A1/en active Pending
- 2023-03-02 CA CA3254024A patent/CA3254024A1/en active Pending
- 2023-03-02 IL IL315361A patent/IL315361A/en unknown
- 2023-03-02 CN CN202380034852.XA patent/CN119053337A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Leng et al. | Interleukin-11 inhibits macrophage interleukin-12 production | |
| Raeber et al. | The role of cytokines in T‐cell memory in health and disease | |
| Street et al. | Functional diversity of T lymphocytes due to secretion of different cytokine patterns | |
| Oppenheim | Cytokines: past, present, and future | |
| Donnelly et al. | Inhibition of IL-10 expression by IFN-γ up-regulates transcription of TNF-α in human monocytes | |
| Hoebe et al. | LPS, dsRNA and the interferon bridge to adaptive immune responses: Trif, Tram, and other TIR adaptor proteins | |
| Atkins et al. | Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. | |
| Turner et al. | Transforming growth factor β induces the production of interleukin 6 by human peripheral blood mononuclear cells | |
| Chung | Anti‐inflammatory cytokines in asthma and allergy: interleukin‐10, interleukin‐12, interferon‐γ | |
| Sikora et al. | IFN-α enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity | |
| Cameron et al. | Cytokines, chemokines and their receptors | |
| Staeheli et al. | Cytokines of birds: conserved functions—a largely different look | |
| Sheen et al. | TLR-induced murine dendritic cell (DC) activation requires DC-intrinsic complement | |
| JP2025507939A5 (https=) | ||
| Danzer et al. | Cytokine interactions in human mixed lymphocyte culture | |
| US20040247563A1 (en) | Method of enhancing lymphocyte-mediated immune responses | |
| Morinaga et al. | Contribution of IL-6 to the antiproliferative effect of IL-1 and tumor necrosis factor on tumor cell lines. | |
| Kremer et al. | lnterleukin-1-6 and tumor necrosis Factor-α release is down-regulated in whole blood from septic patients | |
| Lai et al. | Cytokine production by peripheral blood mononuclear cells in IgA nephropathy | |
| Sanchez et al. | Expression of inducible CC chemokines in rainbow trout (Oncorhynchus mykiss) in response to a viral haemorrhagic septicemia virus (VHSV) DNA vaccine and interleukin 8 | |
| Laskarin et al. | Physiological role of IL-15 and IL-18 at the maternal-fetal interface | |
| Oppenheim | Cytokines, their receptors and signals | |
| Frasca et al. | In vivo restoration of T cell functions by human IL-1 beta or its 163-171 nonapeptide in immunodepressed mice. | |
| Tagliabue et al. | Cytokines as vaccine adjuvants: interleukin 1 and its synthetic peptide 163–171 | |
| Digel et al. | Receptors for tumor necrosis factor on neoplastic B cells from chronic lymphocytic leukemia are expressed in vitro but not in vivo |